Cell-based Assays: Technologies and Global Markets

Report Highlights

The global market for cell-based assays reached $15.2 billion in 2015. This market is expected to increase from $17.1 billion in 2016 to nearly $28.4 billion in 2021 at a compound annual growth rate (CAGR) of 10.6% for 2016-2021.

Report Includes

• An overview of the global markets and related technologies for cell-based assays.
• Analyses of global market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
• Examinations of major issues involved in the research and development (R&D) of more effective cell-based approaches, for drug discovery and absorption, distribution, metabolism, and excretion (ADME)/ toxicity assays in development and in use.
• The current market status of cell-based assays in terms of strengths, weaknesses, opportunities and threats facing various assays and developments already on the market.
• Discussion of current issues and trends affecting the industry, and costs and other factors influencing demand.
• Coverage of new technologies, trends, alliances, and mergers.
• Profiles of major players in the industry.

Report Scope

This report is an update on the earlier report: Cell-based Assays: Technologies and Global Markets. It reviews global markets for cell-based assays and new developments and forecasts trends for use of these assays for drug discovery, safety and toxicology through 2021. The report includes important assays, technologies and the latest developments and market share by assay type and company, with a special emphasis on the U.S. market. Statistical information on the types of cancers prevalent worldwide is also included.

The report also includes current issues and trends affecting the industry, costs and factors influencing demand. It covers products in development, new technologies, trends, and alliances and mergers. The report offers market data by segment and region. It also provides market trends with respect to drivers, restraints and opportunities.

Analyst Credentials

Usha Nagavarapu is an experienced pharmaceutical professional with business development experience. She has preclinical, alliance management, discovery and technology development and marketing experience. Her strong focus areas include oncology and cardiovascular disease, with expertise in molecular and cell biology and complex cell-based biological assays for drug discovery, in vitro and in vivo screening, in vivo model development and pharmacokinetics. She has experience working with early start-ups.